KROS
Keros Therapeutics Inc

1,237
Mkt Cap
$660.81M
Volume
1.12M
52W High
$72.37
52W Low
$9.12
PE Ratio
14.06
KROS Fundamentals
Price
$21.69
Prev Close
$20.27
Open
$20.26
50D MA
$16.25
Beta
0.88
Avg. Volume
1.33M
EPS (Annual)
-$5.00
P/B
1.25
Rev/Employee
$21,005.92
Loading...
Loading...
News
all
press releases
Keros Therapeutics (NASDAQ:KROS) Trading Up 12% - Here's Why
Keros Therapeutics (NASDAQ:KROS) Shares Up 12% - Here's Why...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00
Bank of America raised their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a "neutral" rating in a report on Friday...
MarketBeat·9d ago
News Placeholder
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
Zacks·10d ago
News Placeholder
KROS or NVZMY: Which Is the Better Value Stock Right Now?
KROS vs. NVZMY: Which Stock Is the Better Value Option?
Zacks·12d ago
News Placeholder
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·12d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's Why
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Time to Sell...
MarketBeat·18d ago
News Placeholder
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS
Los Angeles Capital Management LLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·22d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS
Connor Clark & Lunn Investment Management Ltd. raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 107.4% during the 2nd quarter, according to the company in its most...
MarketBeat·22d ago
News Placeholder
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer
Oppenheimer restated an "outperform" rating and issued a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research report on Wednesday...
MarketBeat·25d ago
News Placeholder
5 Undervalued Stocks That Are Poised for Growth in November
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
Zacks·25d ago

Latest KROS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.